A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Background Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks in...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:BMC cancer Ročník 24; číslo 1; s. 82 - 7
Hlavní autori: Mastall, Maximilian, Roth, Patrick, Bink, Andrea, Fischer Maranta, Angela, Läubli, Heinz, Hottinger, Andreas Felix, Hundsberger, Thomas, Migliorini, Denis, Ochsenbein, Adrian, Seystahl, Katharina, Imbach, Lukas, Hortobagyi, Tibor, Held, Leonhard, Weller, Michael, Wirsching, Hans-Georg
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 15.01.2024
BioMed Central Ltd
Springer Nature B.V
BMC
Predmet:
ISSN:1471-2407, 1471-2407
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Buďte prvý, kto okomentuje tento záznam!
Najprv sa musíte prihlásiť.